Prostate Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prostate Cancer (Oncology) pipeline guide also reviews key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 98, 108, 6, 247, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 15, 58 and 20 molecules, respectively.
Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Prostate Cancer - Overview
- Prostate Cancer - Therapeutics Development
- Prostate Cancer - Therapeutics Assessment
- Prostate Cancer - Companies Involved in Therapeutics Development
- Prostate Cancer - Drug Profiles
- Prostate Cancer - Dormant Projects
- Prostate Cancer - Discontinued Products
- Prostate Cancer - Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/pg8s3k/prostate_cancer